The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 308-318

  Sanderink, Ger Jan ^a,b   Liboux, Aimé Le ^a,b   Jariwala, Navin ^a,b   Harding, Neasa ^a,b   Ozoux, Marie Laure ^a,b   Shukla, Umesh ^a,b   Montay, Guy ^a,b   Boutouyrie, Bruno ^a,b   Miro, Adelaida ^a,b  

^a SANOFI   (France)

^b Novum Pharmaceutical Research Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG INFUSION; DRUG MECHANISM; FEMALE; HEIGHT; HUMAN; MALE; OBESITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; STEADY STATE; TIME; VOLUNTEER;

ADOLESCENT; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ENOXAPARIN; FACTOR XA; HUMAN EXPERIMENTATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OBESITY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0036738186     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127114     Document Type: Article

References (37)

1. Heparin and low-molecullar-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
2. Management of venous and cardiovascular thrombosis: Enoxaparin
3. Enoxaparin: A review of its clinical potential in the management of coronary artery disease
4. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction
5. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease
6. Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: Enoxaparin
7. The role of low-molecular weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin
8. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11b trial
9. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
10. Heparin kinetics: Variables related to disposition and dosage
11. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
12. Differential pharmacokinetics of enoxaparin in normal volunteers of ideal body weight 80-100% and greater than or equal to 130% of ideal body weight
13. Lean body mass as a predictor of drug dosage. Implications for drug therapy
14. A formula to estimate the approximate surface area if height and weight be known
15. Heparin therapy adjusted for body weight
16. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight?
17. Dosing and monitoring of low-molecular-weight heparins in special populations
18. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - A three way cross over study in human volunteers
19. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies
20. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins
21. The meaning and measurement of lean body mass
22. Lean body mass
23. Compartmental body composition based on total-body nitrogen, potassium and calcium
24. Body fatness, relative weight and frame size in young adults
25. Lean body mass in obesity
26. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis
27. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
28. Clinical pharmacokinetics of drugs in obesity
29. Low-molecular weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
30. Pharmacokinetics of drugs in obesity
31. Drug disposition in obese humans. An update
32. Digoxin disposition in obesity: Clinical pharmacokinetic investigation
33. The effect of body weight on dalteparin pharmacokinetics. A preliminary study
34. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
35. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies
36. No change in pharmacokinetic profile of enoxaparin when used as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Results of the AMI-SK study
37. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis